BioSyent Releases Financial Results for Q3 and YTD 2025

Executive Summary

• BioSyent Inc. released its financial results for the third quarter and year-to-date period ended September 30, 2025, reporting significant growth across all business segments.
• Total Company Sales increased by 28% in Q3 2025 compared to Q3 2024, reaching CAD 12.2 million, while EBITDA rose 27% to CAD 3.6 million.
• The company declared a subsequent cash dividend of $0.05 per common share, payable on December 15, 2025, and reported strong balance sheet metrics including a 47% increase in cash and short-term investments.

Key Details

• Q3 2025 Financial Performance:
  • Total Company Sales: CAD 12,221,804 (+28% vs Q3 2024).
  • EBITDA: CAD 3,632,399 (+27% vs Q3 2024).
  • Net Income After Taxes (NIAT): CAD 2,682,340 (+16% vs Q3 2024).
  • Fully Diluted EPS: CAD 0.23 (+19% vs Q3 2024).
  • EBITDA Margin: 30% of sales.
• Year-to-Date (YTD) 2025 Performance:
  • Total Company Sales: CAD 33,380,060 (+27% vs YTD 2024).
  • EBITDA: CAD 9,594,195 (+35% vs YTD 2024).
  • Net Income After Taxes (NIAT): CAD 7,020,444 (+24% vs YTD 2024).
  • Fully Diluted EPS: CAD 0.61 (+28% vs YTD 2024).
  • EBITDA Margin: 29% of sales.
• Trailing Twelve Months (TTM) Performance:
  • Total Company Sales: CAD 42,176,744 (+22% vs TTM Sept 30, 2024).
  • EBITDA: CAD 11,835,307 (+35% vs TTM Sept 30, 2024).
  • Net Income After Taxes (NIAT): CAD 8,633,638 (+21% vs TTM Sept 30, 2024).
  • Return on Average Equity: 22% (vs 20% in prior year).
• Segment Sales Breakdown (Q3 2025):
  • Canadian Pharma Sales: CAD 9,864,254 (+19%).
  • International Pharma Sales: CAD 1,153,742 (+94%).
  • Legacy Business Sales: CAD 1,203,808 (+83%).
• Balance Sheet Highlights (As of Sept 30, 2025):
  • Cash, cash equivalents, and short-term investments: CAD 23,395,434 (+47% vs Dec 31, 2024).
  • Total Assets: CAD 47,785,381 (+16% vs Dec 31, 2024).
  • Total Equity: CAD 39,902,869 (+14% vs Dec 31, 2024).
• Corporate Actions:
  • Repurchased 19,500 common shares for cancellation under a Normal Course Issuer Bid (NCIB) during YTD 2025.
  • Paid quarterly cash dividends of $0.05 per share on March 14, June 13, and September 15, 2025.
  • Declared subsequent cash dividend of $0.05 per common share to be paid on December 15, 2025.

Notable Quotes

• “BioSyent delivered strong third quarter financial results... Each of our three businesses performed well during the quarter, with total Company sales increasing by 28% overall. Though we experienced some gross margin compression on changes in sales mix, our overall EBITDA¹ margin in Q3 2025 remained consistent with the comparative period at 30% to sales as operating expenses were maintained in proportion to sales growth.” — René Goehrum, President and CEO